Endoscopic diagnosis of refractory ulcerative colitis

被引：12

作者：

Hirata I. ^{[1
]}

Murano M. ^{[2
]}

机构：

[1] Department of Gastroenterology, FUJITA Health University, Fujita

[2] 2nd Department of Internal Medicine, Osaka Medical College, Takatsuki City, Osaka 569-8686

来源：

Inflammopharmacology | 2007年 / 15卷 / 1期

关键词：

Ulcerative Colitis; Proximal Colon; Endoscopic Diagnosis; Toxic Megacolon; Endoscopic Characteristic;

D O I：

10.1007/s10787-006-1555-z

中图分类号：

学科分类号：

摘要：

Background & AIM: To make the endoscopic characteristics and clinical appearance of refractory ulcerative colitis (UC) clear, we studied the frequency and location of refractory lesions of severe UC patients. Methods: The subjects were a total of 68 patients with severe UC. 41patients were identified with refractory UC, defined as poor response to high-dose systemic steroids (SH-resistant UC), and another group of 27 patients had non-refractory UC (SH-responsive UC). Two groups were compared by the following item; endoscopic findings, locations, effect of treatment, and relation to CMV infection. Results: In SH-resistant UC, longitudinal ulcer and extensive mucosal abrasion were found with high frequency, and there were refractory lesion significantly in proximal colon. In case of UC with refractory lesion, there is a high possibility that treatment is ineffective. Of 14 UC patients with refractory lesion treated with LCAP, 10 obtained remission, whereas only 12 of 30 those patients with treated by only steroids achieved remission. Of 11 steroid-refractory UC patients with CMV detected, were refractory to steroids and had undergone. Conclusions: The findings of this study suggest that it is very important to decide on a patient's medication by relying on exact diagnosis concerning the condition of UC by endoscopy. © 2007 Birkhäuser Verlag.

引用

页码：22 / 25

页数：3

共 6 条

[1]

Matts S.F.G., The value of rectal biopsy in the diagnosis of ulcerative colitis, Quarterly J. Med, 30, pp. 393-407, (1961)

[2]

Farmer R.G., Ulcerative colitis: Complications, Bockus Gastroenterology, pp. 2187-2199, (1985)

[3]

Oshitani N., Kitano A., Nakamura S., Et al., Predictive factors for the response of ulcerative colitis patients during the acute-phase treatment, Digestion, 46, pp. 107-113, (1990)

[4]

Wada Y., Matsui T., Matake H., Et al., Intractable ulcerative colitis caused by cytomegalovirus infection: A prospective study on prevalence, diagnosis, and treatment, Dis. Colon. Rectum, 46, (2003)

[5]

Van Assche G., D'Haens G., Noman M., Et al., Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis, Gastroenterology, 125, pp. 1025-1031, (2003)

[6]

Watanabe K., Inagawa M., Jinno Y., Et al., Efficacy and effective endoscopic findings of granulocyte and monocyte absorption apheresis (GCAP) and leukocytapheresis (LCAP) therapy in patients with refractory active ulcerative colitis (UC), Gut, 53, SUPPL.EMENT, (2004)

← 1 →